Deodato, M.; Frustaci, A.M.; Zamprogna, G.; Cotilli, G.; Cairoli, R.; Tedeschi, A.
Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy? Hemato 2022, 3, 689-703.
https://doi.org/10.3390/hemato3040046
AMA Style
Deodato M, Frustaci AM, Zamprogna G, Cotilli G, Cairoli R, Tedeschi A.
Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy? Hemato. 2022; 3(4):689-703.
https://doi.org/10.3390/hemato3040046
Chicago/Turabian Style
Deodato, Marina, Anna Maria Frustaci, Giulia Zamprogna, Giulia Cotilli, Roberto Cairoli, and Alessandra Tedeschi.
2022. "Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy?" Hemato 3, no. 4: 689-703.
https://doi.org/10.3390/hemato3040046
APA Style
Deodato, M., Frustaci, A. M., Zamprogna, G., Cotilli, G., Cairoli, R., & Tedeschi, A.
(2022). Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy? Hemato, 3(4), 689-703.
https://doi.org/10.3390/hemato3040046